Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less

esmo - Findings from the POSEIDON meta-analysis of the MARCAP consortium

AI Summary: A pooled POSEIDON meta-analysis from the MARCAP consortium found that adding androgen-deprivation therapy to post‑operative radiotherapy for recurrent prostate cancer with PSA ≤0.5 ng/mL does not improve outcomes meaningfully. In short: the extra hormonal punch may not be worth the side effects many patients will endure.